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Human immunodeficiency virus (HIV) prevention programmes
for injection drug users (IDU) have included elements such as
outreach education, testing, counselling, bleach distribution, and
wider access to sterile needles through unrestricted pharmacy
access and needle exchange programmes. Needle exchange
programmes work by providing sterile in exchange for con-
taminated needles alongside outreach education and health
service referrals. With both HIV and hepatitis viruses known to be
transmitted by multiperson use of needles and syringes, provid-
ing access to sterile needles for those who cannot or will not
stop drug use would appear to be an important strategy. An
early observational study of the effectiveness of needle exchange
programmes showed that harm reduction was associated with
reduced rates of hepatitis B and C virus infections,1 and other
observational studies have shown lower rates of HIV.2,3 However,
subsequent work has shown that this is not always the case4 and
that rates of hepatitis C virus (HCV) in IDU have tended to
remain elevated even in communities where HIV rates have
declined.5 This discrepancy has been puzzling, and the modelling
study by Murray and coworkers in this issue provides a con-
tribution to advance our thinking about this.6
Although both HIV and HCV share similarities in that drug
users are at risk through parenteral transmission and both are
predominantly chronic infections, there are important differ-
ences between the two infections. First, the prevalence of infec-
tion among drug users is higher for HCV than for HIV, indicating
a larger pool of HCV from which transmission can occur.
Second, data from needlestick injuries suggest that the rate of
transmission per individual needle stick may be about 10 times
higher in HCV than HIV infection.7 Third, indirect sharing and
drug preparation practices such as backloading and sharing of
the cotton, cooker, and rinse water used to prepare drugs for
injection are more frequently associated with transmission of
HCV5,8 than HIV.9 One report indicating the possibility of trans-
mission with straws used to inhale cocaine suggests an efficiency
of transmission for HCV that has not been reported to date for
HIV.10
Murray et al. suggest that these known or suspected
epidemiological differences did not fully explain the intriguing
situation in Australian injection drug users where the reported
HIV prevalence remained very low,11 but HCV prevalence was
about 50% and comparable to that observed in other injection
drug user populations with much higher HIV prevalence. To
explain this situation they modelled virus transmission among
injection drug users via ‘classic’ needle sharing in such a way as
to handle both HCV and HIV while capturing the main differ-
ences between the two. An interesting approach was chosen by
modelling drug sharing episodes among groups of a given size.
The model allowed for calculating critical levels of needle sharing
below which total infections would fall to a low prevalence.
These levels were estimated to be 17 injection partners per year
for HIV and 3 for HCV and were compared to 6 injection
partners per year currently estimated in Australia.
Mathematical propagation models such as this have a number
of uses. First, they can provide qualitative insights into the
relevance of certain key parameters or structural aspects of the
dynamics of propagation. The results of this study indicate that
behavioural changes in needle sharing starting in the late 1980s
in Australia might have been enough to limit the spread of HIV
but insufficient to substantially limit or reduce HCV prevalence.
Second, modelling may provide the public health community
with quantitative predictions of the possible effect of intervention
strategies to assist policymaking. Here, the model estimates 
the number and prevalence of HIV and HCV infections in the
injection drug user population of Australia (Figure 2) and the
critical level of needle sharing necessary for successfully reducing
these infections. The authors should be applauded for having
provided estimates of the uncertainty of some of their results, a
feature not always included in such modelling studies. How-
ever, the uncertainty for HCV prevalence was considerable,
with an inter quartile range from 20 to 50% for the year 2000,
and these estimates were much more imprecise than those for
HIV prevalence (Figure 2). It would have been important to
know which of the parameters and their uncertainty was prim-
arily responsible for this substantial difference. No estimates on
uncertainty of the critical levels of needle sharing were given,
however. These would have enabled better judgement of
whether the critical level of three partners per year can indeed
be expected to reduce HCV to low levels.
As mathematical modelling studies are inevitably based on
assumptions, one can always argue about how appropriate
these are, and whether they are unrealistic or too simplistic and
therefore hamper firm qualitative or quantitative conclusions
about the reality. Here, the authors chose to build the model on
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parameters that reflect the average value over all injection drug
users in Australia. For example, the average number of
injections per year was chosen to be 60, with a range of 30 to 90.
This value was based on cross-sectional data on self-reported
needle sharing within the last month and some model-specific
equations that allowed this information to be related to the
number of injections. Given the heterogeneity in drug con-
sumption intensity between sporadic, regular, and heavily drug
dependent injectors, this may be too strong a simplification.
More complex compartment modelling would have been neces-
sary to account for that. Additionally, per contact infectivity was
assumed to be 2% (0.3–3.3%) for HIV and 4% (1.2–10%) for
HCV (Table 1), and constant after infection. However, not all
HCV infected individuals remain persistently infected and contact
infectivity seems to be higher with higher levels of viral load12
and can be expected to be much higher in acute viraemia after
infection. Incorporating acute viraemia may be necessary to
adequately explain the fact that HCV may be transmitted rapidly
in the first few years after initiation of injection use, or among
very young injectors.11,13
In conclusion, the US Public Health Service have issued an
HIV Prevention Bulletin14 to warn injection drug users who
could not quit using drugs to use (and then discard) a new
sterile needle each time they injected. While rates of HIV have
declined, the persistent high rates of HCV and the concern
about transmission with even a few partners suggested in this
modelling exercise indicate that efforts to encourage single use
and discard syringes remain important.
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